Skip to main
ACLX

Arcellx (ACLX) Stock Forecast & Price Target

Arcellx (ACLX) Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 67%
Buy 22%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Arcellx Inc. has demonstrated robust growth in its commercial offerings, highlighted by a remarkable 32% average quarter-over-quarter sales increase for Carvykti over the past three years, alongside a significant year-over-year revenue growth of 214%. The increasing adoption of CAR T therapy among community physicians, rising from 29% to 47%, indicates a strengthening market presence and potential for broader accessibility to advanced treatments. Furthermore, the anticipated clinical efficacy of anito-cel alongside other promising data reinforces a positive outlook, with projections suggesting the potential for substantial market share and significant revenue generation by 2035.

Bears say

Arcellx Inc faces significant challenges due to high rates of Grade 3-4 infections observed in its clinical trial MajesTEC-1, which could hinder patient adoption and overall treatment success. Additionally, the company's market share estimates for its product anito-cel are in line with consensus figures, yet its projected sales figures for the CAR T market in myeloma are notably below consensus, indicating potential revenue shortfalls. Furthermore, barriers to patient access and adoption in community settings, coupled with uncertainties around the development of additional clinical candidates, suggest a compromised growth trajectory and contribute to a negative outlook for the stock.

Arcellx (ACLX) has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 22% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Arcellx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Arcellx (ACLX) Forecast

Analysts have given Arcellx (ACLX) a Strong Buy based on their latest research and market trends.

According to 9 analysts, Arcellx (ACLX) has a Strong Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $112.22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $112.22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Arcellx (ACLX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.